HR+/HER2- breast cancer with mutant TP53 – validation of aberrant immunohistochemistry as a surrogate marker and association with non-luminal molecular subtypes

E Weisser, N Böhme, S Jürges, V Gassenmaier, I Götting, S Matovina, L-L Volmer, H Armbruster, T Engler, A Koch, M Overkamp, V Bahlinger, J Milla, I A Montes Mojarro, R Rottscholl, I Bonzheim, S Brucker, A Hartkopf, F Fend, A Staebler · Senologie - Zeitschrift für Mammadiagnostik und -therapie · 2026 · Heft 02 · S. e45